TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03608371
Drug: BTRX-246040
Normalized name: BTRX-246040
DrugBank: BTRX-246040 (DB16048)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral capsule 40 mg
Study: NCT01743365
Drug: Cisplatin-5FU-Afatinib
Normalized name: Afatinib
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04514029
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrathecal dexamethasone 8 mg on days -1, +6, +13 (+/-2 days)
Study: NCT03819153
Drug: Semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants are to inject semaglutide with a needle in the stomach, thigh or upper arm. Participants will use a pen to inject semaglutide under their skin. Participants will inject semaglutide 1 time a week on the same day of the week. Participants' dose of semaglutide will be changed over time. Participants start by taking a smaller amount (0.25 mg). After 4 weeks the dose will be increased to 0.5 mg. It will be increased more (to 1 mg) at 8 weeks. Participants will then stay on the same dose for the rest of the study.
Study: NCT00503516
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol acetate (DB00351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 sachet of powder containing 160 mg of megestrol acetate b.i.d. during 24 weeks
Study: NCT00954304
Drug: Loperamide 2mg
Normalized name: LOPERAMIDE 2MG/SIMETH 125MG CHEW TAB
DrugBank: Loperamide (DB00836)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loperamide 2mg capsule
Study: NCT03229031
Drug: ES135
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ES135 will be administered via intrathecal
Study: NCT02855073
Drug: Sodium Hyaluronate
Normalized name: sodium hyaluronate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium Hyaluronate Injection
Study: NCT04099407
Drug: Pirfenidone
Normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treatment consist of 600 mg tablets of a prolonged-released formulation of Pirfenidone. Patients are instructed to take medication orally, every 12 h, after breakfast and dinner.
Study: NCT04074135
Drug: 68-Gallium DOTATATE
Normalized name: Gallium 68 dotatate
DrugBank: Gallium nitrate (DB05260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 68-Gallium DOTATATE, to be used in yearly PET/CT research scans
Study: NCT04525729
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: To evaluate the efficacy and safety of HLX01 combined with RASi in patients with IgAN.
Study: NCT04525729
Drug: RAS 2410
Normalized name: RAS
DrugBank: Rasagiline (DB01367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: To evaluate the efficacy and safety of RASi in patients with IgAN.
Study: NCT03094403
Drug: Azelaic Acid 15% topical gel
Normalized name: Azelaic Acid 15% Topical gel
DrugBank: Azelaic acid (DB00548)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gel
Study: NCT01527539
Drug: biphasic insulin aspart 30
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose individually adjusted. Injected twice daily immediately before breakfast and dinner. Administrated subcutaneously (s.c., under the skin)
Study: NCT02275988
Drug: K-877
Normalized name: MK-8776
DrugBank: MK-8776 (DB11899)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00090168
Drug: Comparator: atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00001624
Drug: Insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00634400
Drug: Candesartan
Normalized name: Candesartan
DrugBank: Candesartan (DB13919)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02555709
Drug: VTP-43742
Normalized name: VTP-201227
DrugBank: VTP-201227 (DB05652)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VTP-43742 administered as an oral capsule once daily
Study: NCT00660621
Drug: Temozolomide and Bevacizumab
Normalized name: Temozolomide
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Between 14 and 28 days after surgery, all subjects will begin a standard course of post-operative limited field radiation therapy to the tumor site and a surrounding margin with concomitant temozolomide at a daily dose of 75 mg/m2 (7 days/week).~No later than 45 days after date of completion of radiation therapy, all subjects will begin dose dense temozolomide at dose of 150 mg/m2 on Days 1-7 and 15-21 of a 28 day cycle with concomitant bevacizumab 10mg/kg administered intravenously every other week.
Study: NCT00691002
Drug: Calcipotriol
Normalized name: Calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02616562
Drug: somapacitan
Normalized name: Somapacitan
DrugBank: Somapacitan (DB15093)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered subcutaneously (s.c., under the skin) once-weekly.
Study: NCT03749902
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * An initial dose of misoprostol 25mcg will be given orally after randomisation (this must be a minimum of 2 hours after the previous misoprostol dose).~* The next dose of oral misoprostol will be omitted if moderate or strong contractions are occurring at 3 in 10 minutes or more (i.e. 9 or more in the preceding 30 minutes)~* If contractions subsequently reduce to less than 3 in 10 (under 9 in 30 minutes), or become irregular or mild, then the oral misoprostol 25mcg can be restarted~* In the event of inadequate progress, clinicians will be advised to give further misoprostol if there are any concerns about contractions strength or frequency.
Study: NCT03749902
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Oxytocin infusion will be given through an electronic infusion pump. One unit of oxytocin will be injected in 500 mL of Ringer's lactate, started at a rate of 2 mU/min, and increased every 30 min by 2 mU/min until there are three to four contractions every 10 min. The rate will be titrated to maintain that contraction frequency. The maximum dose will be 20mU/min as oxytocin summary product characteristics.~* The oxytocin group will not receive misoprostol after the membranes have ruptured.
Study: NCT03387475
Drug: Deferasirox
Normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: iron chelation
Study: NCT02444533
Drug: Liposomal Bupivacaine
Normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection of 8 ml of liposomal bupivacaine total in the tonsillar fossae after tonsillectomy.
Study: NCT00962299
Drug: Beclomethasone
Normalized name: Beclomethasone
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclometasone 100 ug b.i.d. by metered dose inhaler with spacer for 6 months
Study: NCT03834584
Drug: AG-636
Normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AG-636 will be administered orally intermittently in 28-day cycles.
Study: NCT00664469
Drug: ezetimibe
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ezetimibe 10 mg/day over a 6-week course of treatment.
Study: NCT00664469
Drug: Comparator: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin 20, 40 \& 80 mg; actual statin regimen for 6 weeks followed by another 6 weeks if at goal or statin dose can be doubled.
Study: NCT01195922
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 21 evaluable subjects will take rapamycin (sirolimus) orally once per day for 21 days. Before and after dosing tumor assessments to include: photographs, CT \& amp; PET scans will be done for tumor measurement.
Study: NCT00743067
Drug: GSK1363089 (formerly XL880)
Normalized name: Lor-253(former code)
DrugBank: APTO-253 (DB17143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1363089 will be available as solid capsules with dose unit of 20, 100 and 200 mg. Subjects will administer GSK1363089 capsules orally
Study: NCT03418038
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV or PO
Study: NCT03418038
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV or PO
Study: NCT03418038
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV or PO
Study: NCT03418038
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV or PO
Study: NCT03418038
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV or PO
Study: NCT03418038
Drug: Gemcitabine Hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV or PO
Study: NCT03418038
Drug: Ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV or PO
Study: NCT03418038
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV or PO
Study: NCT03418038
Drug: Decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03617731
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 25 mg per os on day 1-14 and d22-35 in induction cycle 1-3 (Arms IA and IB) 10 mg p.o. on day 1-28 in maintenance cycle 1-3, 15 mg p.o. on day 1-28 in maintenance cycle 4-39 (Arms IIA and IIB)
Study: NCT03617731
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: all arms: 1,3 mg/m\^2 subcutaneous on day 1, 4, 8, 11, 22, 25, 29 32 in 3 induction cycles
Study: NCT01154153
Drug: Triamcinolone acetonide aqueous (TAA-AQ) nasal spray (NASACORT AQ)
Normalized name: triamcinolone acetonide Metered Dose Nasal Spray
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment assignment was randomized with stratification by sex and age group (\>=2 to \<6, \>=6 to \<12 years old).~* For children who were \>=2 to \<6 years old, 1 spray/nostril (110 µg TAA-AQ), once daily in the morning, for 6 weeks, during the double-blind treatment phase.~* For children who were \>=6 yrs to \<12 years old, either 1 spray/nostril (110 µg TAA-AQ) or 2 sprays/nostril (220 µg TAA-AQ), once daily in the morning, for 6 weeks, during the double-blind treatment phase.
Study: NCT03164590
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients receive local anesthetic wound infiltration with 1 mg /kg ketamine
Study: NCT03164590
Drug: dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: patients receive local anesthetic wound infiltration with 1µg/kg dexmedetomidine
Study: NCT03164590
Drug: bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients receive local anesthetic wound infiltration with bupivacaine 0.5 % diluted in 20 ml saline
Study: NCT00004920
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03617731
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20 mg per os on day 1,2 and 4,5 and 8,9 and 11,12 and 15 and 22,23 and 25,26 and 29,30 and 32,33 in induction cycles 1-3 (Arms IA and IB). Maintenance cycle 1 on day 1, 8, 15, 22 Dexamethasone 20 mg/d per os (Arm IIA). In Arm IIB Dexamethasone 20 mg i.v. on days of Isatuximab infusion in the first maintenance cycle (d 1, 8, 15, 22), dexamethasone will be administered intravenously as part of the premedication. If an isatuximab dose is skipped or discontinued dexamethasone should be administered orally.
Study: NCT03617731
Drug: Isatuximab
Normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10 mg/kg in the vein( i.v) on day 1,8,15, 22, 29 in induction cycle 1 on day 1, 15 and 29 in induction cycle 2 and 3 (Arm IB). 10 mg/kg i.v. on day 1,8, 15 and 22 in maintenance cycle 1, 10 mg/kg i.v. on day 1 and 15 in maintenance cycle 2 and 3, 10 mg/kg i.v. on day 1 in maintenance cycle 4 - 39 (Arm IIB)
Study: NCT00004920
Drug: raltitrexed
Normalized name: raltitrexed
DrugBank: Raltitrexed (DB00293)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00335920
Drug: Dexamethasone-dihydrogenphosphate (4mg/ml)
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04233463
Drug: Budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Standard treatment for mild Crohn Disease patients
Study: NCT02152787
Drug: Injection of propofol 1.0mg/kg
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02152787
Drug: propofol 0.5mg/kg
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00359437
Drug: Satavaptan
Normalized name: Satavaptan
DrugBank: Satavaptan (DB14923)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration once daily
Study: NCT03103009
Drug: Pasireotide
Normalized name: Pasireotide
DrugBank: Pasireotide (DB06663)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Somatostatin analogues are a last resort for medical intervention in hyperinsulinemic hypoglycemia (HH). The hypoglycemia is very debilitating and can be even life threatening. There is limited experience with pasireotide in hyperinsulinemic hypoglycemia (only one publication); there is more experience with octreotide, both in adults and children and successful interventions with octreotide in hyperinsulinemic hypoglycemia have been published. Pasireotide via its different somatostatin receptor binding profile has clear effects on insulin, glucagon and incretin secretion and can ultimately lead to hyperglycemia. This mode of action (especially the effects on insulin and incretin secretion) could be very useful in the setting of hyperinsulinemic hypoglycemia.
Study: NCT03128593
Drug: JR-141
Normalized name: IMMUNOGLOBULIN G1, ANTI-(HUMAN TRANSFERRIN RECEPTOR) (HUMAN-MUS MUSCULUS MONOCLONAL JR-141 .GAMMA.1-CHAIN) FUSION PROTEIN WITH PEPTIDE (SYNTHETIC 2-AMINO ACID LINKER) FUSION PROTEIN WITH HUMAN IDURONATE-2-SULFATASE, DISULFIDE WITH HUMAN-MUS MUSCULUS MONO
DrugBank: Pabinafusp alfa (DB15633)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: IV infusion (lyophilized powder), 0.01-2.0 mg/kg/week
Study: NCT02141178
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03475680
Drug: Sennosides colonic preparation
Normalized name: Sus scrofa colon preparation
DrugBank: Sennosides (DB11365)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mechanical bowel preparation :~Sennosides colonic preparation (X-PREP)~1 per day, on day -2 and day -1
Study: NCT03475680
Drug: Oral Ornidazole
Normalized name: ornidazole
DrugBank: Ornidazole (DB13026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Ornidazole :~Ornidazole~1 g per day (2 tablet per day), on day -2 and day -1; In tablets
Study: NCT03475680
Drug: Oral placebo Ornidazole
Normalized name: ornidazole
DrugBank: Ornidazole (DB13026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for oral Ornidazole :~Same presentation as oral ornidazole~1g per day (2 tablet per day) on day -2 and day -1
Study: NCT02141178
Drug: Exparel
Normalized name: Exparel
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02970916
Drug: FOLFIRI+aflibercept
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aflibercept: 4 mg/kg administered intravenous infusion on day 1~FOLFIRI regimen immediately after aflibercept:~Irinotecan:180 mg/m2 intravenous infusion, folinic acid (dl racemic): 400 mg/m2 intravenous infusion, followed by 5-fluorouracil (5-FU): 400 mg/m2 intravenous bolus, followed by 5-FU: 2400 mg/m2 continuous intravenous infusion over 46 hours.~\* folinic acid: 400 mg/m² (racémic) or 200 mg/m² (L-form)
Study: NCT00670878
Drug: 3 x FEC 3 x DOC / Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 cycles of 5-Fluorouracil 500 mg/m² i.v. body surface area and Epirubicin 100 mg/m² i.v. and Cyclophosphamide 500 mg/m² i.v., (FEC100), each administered on day 1, repeated on day 22, subsequently followed by 3 cycles of Docetaxel 75 mg/m² body surface area i.v. (D), and Gemcitabine 1000 mg/m² i.v. (30 min infusion) (G), administered on day 1, followed by Gemcitabine 1000 mg/m² i.v. (30 min infusion) on day 8, repeated on day 22
Study: NCT00670878
Drug: 3 x FEC 3 x DOC
Normalized name: bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 cycles of 5-Fluorouracil 500 mg/m² i.v. body surface area and Epirubicin 100 mg/m² i.v. and Cyclophosphamide 500 mg/m² i.v., (FEC100), each administered on day 1, repeated on day 22, subsequently followed by 3 cycles of Docetaxel 100 mg/m² body surface area i.v. (D), administered on day 1, repeated on day 22
Study: NCT01643083
Drug: Rifaximin
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifaximin 400mg tid for 2 wk
Study: NCT02843074
Drug: elotuzumab
Normalized name: elotuzumab
DrugBank: Elotuzumab (DB06317)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given intravenously (IV)
Study: NCT00887406
Drug: GSK961081 15mcg SD
Normalized name: Alphanine SD
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose delivered via solution for nebulisation
Study: NCT00887406
Drug: GSK961081 3mcg SD
Normalized name: Alphanine SD
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose delivered via nebulsier
Study: NCT00887406
Drug: GSK961081 50mcg SD
Normalized name: Alphanine SD
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose delivered via solution for nebulisation
Study: NCT00887406
Drug: GSK961081 100mcg SD
Normalized name: Alphanine SD
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose delivered via solution for nebulisation
Study: NCT00887406
Drug: GSK961081 200mcg SD
Normalized name: Alphanine SD
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose via nebuliser
Study: NCT00887406
Drug: GSK961081 300mcg SD
Normalized name: Alphanine SD
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose via nebuliser
Study: NCT02843074
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given by IV
Study: NCT02843074
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given orally (PO) or by IV
Study: NCT00005042
Drug: semaxanib
Normalized name: Semaxanib
DrugBank: Semaxanib (DB06436)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01685970
Drug: 2 sachets of picosulfate
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 sachets of picosulfate 2 times for bowel preparation at the day of colonoscopy
Study: NCT01564758
Drug: Linezolid
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1. Vancomycin-resistant, E. faecium, including concurrent bacteremia: Linezolid for 600mg (IV or oral) every 12 hours for 14-28 days~2. Nosocomial infection, cSSTI: Linezolid for 600mg (IV or oral) every 12 hours for 10-14 days~3. Uncomplicated SSTI: Linezolid for 400mg oral every 12 hours for 10-14 days
Study: NCT00887003
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low Volume, Low Dose (5cc, 5mg plain Bupivacaine)
Study: NCT00887003
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low Volume, High Dose (5cc, 10mg plain Bupivacaine)
Study: NCT00887003
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High Volume, Low Dose (10cc, 5mg plain Bupivacaine)
Study: NCT04245514
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Immunotherapy
Study: NCT00887003
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High Volume, High Dose (10cc, 10mg plain Bupivacaine)
Study: NCT00887003
Drug: Depo-Medrol
Normalized name: DEPO-Medrol
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80mg Depo-Medrol
Study: NCT03397654
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab solution
Study: NCT04283578
Drug: OT
Normalized name: Otex
DrugBank: Motexafin lutetium (DB05296)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One group will receive OT for 4 weeks, then placebo or OT for 8 weeks
Study: NCT03206086
Drug: Eltrombopag
Normalized name: Eltrombopag
DrugBank: Eltrombopag (DB06210)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daily dose - Non-Asian (\>=12): 150 mg Non-Asian (6-11): 75 mg East Asian, South East Asian (\>=12): 75 mg East Asian, South East Asian (6-11): 37.5 mg
Study: NCT00058357
Drug: lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01903330
Drug: GM-CSF
Normalized name: GM-CSF
DrugBank: Regramostim (DB05386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given intradermally
Study: NCT01903330
Drug: Bevacizumab/Bevacizumab Biosimilar
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV. Drug class: Immunological Agent; Monoclonal Antibody.
Study: NCT04452799
Drug: Hesperidin and Diosmin mixture
Normalized name: diosmin / hesperidin
DrugBank: Hesperidin (DB04703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interventional Clinical Trial
Study: NCT00343850
Drug: Asacol (mesalamine)
Normalized name: mesalamine Delayed Release Oral Tablet [Asacol]
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04179071
Drug: Savolitinib
Normalized name: savolitinib
DrugBank: Savolitinib (DB12048)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject will receive savolitinib tablet 600mg orally after a high-fat, high-calorie meal.